If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Lipids === Source: The lipid tail is essential for enabling lipid membrane insertion and retention but also for giving the construct amphiphilic characteristics that enable hydrophilic surface coating (due to formation of bilipid layers). Different membrane lipids that can be used to create FSLs have different membrane physiochemical characteristics and thus can affect biological function of the FSL. Lipids in FSL Kode constructs include:
The first submarine not relying on human power for propulsion was the French Plongeur (Diver), launched in 1863, which used compressed air at 1,200 kPa (180 psi). Narcís Monturiol designed the first air-independent and combustion-powered submarine, Ictíneo II, which was launched in Barcelona, Spain in 1864. The submarine became feasible as potential weapon with the development of the Whitehead torpedo, designed in 1866 by British engineer Robert Whitehead, the first practical self-propelled torpedo. The spar torpedo that had been developed earlier by the Confederate States Navy was considered to be impracticable, as it was believed to have sunk both its intended target, and H. L. Hunley, the submarine that deployed it. The Irish inventor John Philip Holland built a model submarine in 1876 and in 1878 demonstrated the Holland I prototype. This was followed by a number of unsuccessful designs. In 1896, he designed the Holland Type VI submarine, which used internal combustion engine power on the surface and electric battery power underwater. Launched on 17 May 1897 at Navy Lt. Lewis Nixon's Crescent Shipyard in Elizabeth, New Jersey, Holland VI was purchased by the United States Navy on 11 April 1900, becoming the Navy's first commissioned submarine, christened USS Holland. Discussions between the English clergyman and inventor George Garrett and the Swedish industrialist Thorsten Nordenfelt led to the first practical steam-powered submarines, armed with torpedoes and ready for military use.
The first published recommendations for protection against radium and radiation in general were made by the British X-ray and Radium Protection Committee and were adopted internationally in 1928 at the first meeting of the International Commission on Radiological Protection (ICRP), following preliminary guidance written by the Röntgen Society. This meeting led to further developments of radiation protection programs coordinated across all countries represented by the commission. Exposure to radium is still regulated internationally by the ICRP, alongside the World Health Organization. The International Atomic Energy Agency (IAEA) publishes safety standards and provides recommendations for the handling of and exposure to radium in its works on naturally occurring radioactive materials and the broader International Basic Safety Standards, which are not enforced by the IAEA but are available for adoption by members of the organization. In addition, in efforts to reduce the quantity of old radiotherapy devices that contain radium, the IAEA has worked since 2022 to manage and recycle disused 226Ra sources. In several countries, further regulations exist and are applied beyond those recommended by the IAEA and ICRP. For example, in the United States, the Environmental Protection Agency-defined Maximum Contaminant Level for radium is 5 pCi/L for drinking water; at the time of the Manhattan Project in the 1940s, the "tolerance level" for workers was set at 0.1 micrograms of ingested radium.
For instance, the hedgehog protein activates different genes, depending on the amount of hedgehog protein present. Complex multi-component signal transduction pathways provide opportunities for feedback, signal amplification, and interactions inside one cell between multiple signals and signaling pathways. A specific cellular response is the result of the transduced signal in the final stage of cell signaling. This response can essentially be any cellular activity that is present in a body. It can spur the rearrangement of the cytoskeleton, or even as catalysis by an enzyme. These three steps of cell signaling all ensure that the right cells are behaving as told, at the right time, and in synchronization with other cells and their own functions within the organism. At the end, the end of a signal pathway leads to the regulation of cellular activity. This response can take place in the nucleus or in the cytoplasm of the cell. A majority of signaling pathways control protein synthesis by turning certain genes on and off in the nucleus. In unicellular organisms such as bacteria, signaling can be used to 'activate' peers from a dormant state, enhance virulence, defend against bacteriophages, etc. In quorum sensing, which is also found in social insects, the multiplicity of individual signals has the potentiality to create a positive feedback loop, generating coordinated response. In this context, the signaling molecules are called autoinducers. This signaling mechanism may have been involved in evolution from unicellular to multicellular organisms.
Flaminius had overseen the construction of the road named after him from Bononia (Bologna) to Arretium (Arezzo). Acidinus had conquered the Taurisci in 183. The triumvirate led 3,000 families to settle the area meaning Aquileia probably had a population of 20,000 soon after its founding. Meanwhile, based on the evidence of names chiselled on stone, the majority of colonizing families came from Picenum, Samnium, and Campania, which also explains why the colony was Latin and not Roman. Among these colonists, pedites received 50 iugera of land each, centuriones received 100 iugera each, and equites received 140 iugera each. Either at the founding or not long afterwards, colonists from the nearby Veneti supplemented these families. Roads soon connected Aquileia with the Roman colony of Bologna probably in 173 BC. In 148 BC, it was connected with Genua by the Via Postumia, which stretched across the Padanian plain from Aquileia through or near to Opitergium, Tarvisium, Vicetia, Verona, Bedriacum, and the three Roman colonies of Cremona, Placentia, and Dertona. The construction of the Via Popilia from the Roman colony of Ariminium to Ad Portum near Altinum in 132 BC improved communications still further. In the first century, the Via Gemina would link Aquileia with Emona to the east of the Julian Alps, and by 78 or 79 the Via Flavia would link Aquileia to Pula.
Sources: en.wikipedia.org
=== Janata Party and Bharatiya Janata Party === After the Emergency was lifted, he was elected to the 6th Lok Sabha (1977–1979) on a Janata Party ticket from Kapadvanj but lost that seat in 1980 elections. He was the Vice-President of the Janata Party in Gujarat and from 1980 to 1991 he was the General Secretary and President of the Bharatiya Janata Party (BJP) in Gujarat. He was a member of the Rajya Sabha from 1984 to 1989. In 1989 he was elected to the 9th Lok Sabha (1989–91) from Gandhinagar and in 1991 he was re-elected to the 10th Lok Sabha (1991–96) from Godhra (Lok Sabha constituency). In 1995, BJP won a majority of 121 seats in the 182-member Legislative Assembly. Many party legislators expressed a preference for Vaghela as their leader. However, the BJP leadership installed Keshubhai Patel as the Chief Minister, and the support for Vaghela was gradually eroded. Narendra Modi is said to have thrown his weight behind Keshubhai Patel in preference to Vaghela, and was held responsible for the ensuing events by Vaghela. In September 1995, Vaghela rebelled against the BJP leadership with the support of 47 MLAs. In the subsequent compromise worked out by the leadership, Keshubhai Patel was replaced by a Vaghela loyalist Suresh Mehta as the Chief Minister. Modi was temporarily banished from Gujarat. Vaghela lost Godhra seat in May 1996 Lok Sabha polls, and soon left Bharatiya Janata Party with his supporters, bringing down Suresh Mehta's government.
== International broadcast == The series will be broadcast by Star Chinese Channel outside of China and Mediacorp Channel 8 in Singapore every Saturday, 10:30pm to 12:30am the next day, broadcasting two episodes in a day. It first aired in Thailand on Channel 3 in 2021 daily at 2:50 am starting Friday 27 August, following Eternal Love (rerun) finished.
The Bergmann degradation makes use of the azide degradation described by the Curtius rearrangement. Curtius also attempted to degrade benzoylated amino acids; however, his method involved splitting the carbamate with strongly energetic treatment with acids, which lead to decomposition of the resultant aldehyde and acid amides. This convinced Bergmann that Curtius' azide degradation could be followed by treatment with benzyl alcohol (his carbobenzoxy method) to isolate the resultant amino acid aldehyde and residual peptide amide for sequencing purposes.
This enzyme is the extracellular nuclease of Staphylococcus aureus. Two strains, V8 and Foggi, yield almost identical enzymes. A common source is E.coli cells carrying a cloned nuc gene encoding Staphylococcus aureus extracellular nuclease (micrococcal nuclease). The 3-dimensional structure of micrococcal nuclease (then called Staphyloccal nuclease) was solved very early in the history of protein crystallography, in 1969. Higher-resolution, more recent crystal structures are available for the apo form and for the thymidine-diphosphate-inhibited form. As seen in the ribbon diagram above, the nuclease molecule has 3 long alpha helices and a 5-stranded, barrel-shaped beta sheet, in an arrangement known as the OB-fold (for oligonucleotide-binding fold) as classified in the SCOP database.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.